Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07587814 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy

Study acronym: COCORIVO
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.
Trial Details
NCT Number NCT07587814
Lead Sponsor Centre Henri Becquerel
Conditions
(from sponsor)		 Carcinoma, Castration Resistant Prostatic Neoplasms
Related terms Carcinoma, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov